Collins Stewart Downgrades Human Genome Sciences (HGSI) to Neutral; Survey Suggests Lackluster 2012
Tweet Send to a Friend
Get Alerts HGSI Hot Sheet
Price: $14.24 --0%
Rating Summary:
5 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
5 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade HGSI Now!
Collins Stewart downgraded Human Genome Sciences (NASDAQ: HGSI) to Neutral, price target cut from $17 to $10.
Collins analyst says, "We are presenting the results of our 4Q11 Benlysta tracking survey (N=30), which suggests that 83% of physicians expect to treat an average of 4.6 patients by mid-2012 and 87% expect to treat an average of 11 by YE12 (vs. 53% treating 5.1 in Dec). Extrapolating this to the 2.3K target physicians suggests FY12 Benlysta sales of ~$197.1M (likely an overestimation, as 87% of physicians in our survey are academic-based and potentially early adopters) vs. consensus of $216.1M and CSe of $213.5M."
For an analyst ratings summary and ratings history on Human Genome Sciences click here. For more ratings news on Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $8.36 yesterday, with a 52 week range of $6.51-$30.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Collins analyst says, "We are presenting the results of our 4Q11 Benlysta tracking survey (N=30), which suggests that 83% of physicians expect to treat an average of 4.6 patients by mid-2012 and 87% expect to treat an average of 11 by YE12 (vs. 53% treating 5.1 in Dec). Extrapolating this to the 2.3K target physicians suggests FY12 Benlysta sales of ~$197.1M (likely an overestimation, as 87% of physicians in our survey are academic-based and potentially early adopters) vs. consensus of $216.1M and CSe of $213.5M."
For an analyst ratings summary and ratings history on Human Genome Sciences click here. For more ratings news on Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $8.36 yesterday, with a 52 week range of $6.51-$30.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Jefferies Downgrades Limited Brands (LTD) to Underperform; Sees 21% Downside
- SunTrust Robinson Humphrey Downgrades Zimmer Holdings (ZMH) to Reduce
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Collins Stewart
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
